Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Raiffeisen Bank International AG

Raiffeisen Bank International AG cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 16.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,000 shares of the specialty pharmaceutical company’s stock after selling 1,522 shares during the period. Raiffeisen Bank International AG’s holdings in Jazz Pharmaceuticals were worth $857,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. CWM LLC grew its stake in Jazz Pharmaceuticals by 56.2% during the 1st quarter. CWM LLC now owns 1,259 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 453 shares during the last quarter. Y Intercept Hong Kong Ltd grew its position in shares of Jazz Pharmaceuticals by 269.5% during the first quarter. Y Intercept Hong Kong Ltd now owns 9,721 shares of the specialty pharmaceutical company’s stock worth $1,207,000 after acquiring an additional 7,090 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $10,900,000. KLP Kapitalforvaltning AS increased its holdings in shares of Jazz Pharmaceuticals by 1.8% in the 1st quarter. KLP Kapitalforvaltning AS now owns 17,300 shares of the specialty pharmaceutical company’s stock valued at $2,148,000 after acquiring an additional 300 shares during the period. Finally, Readystate Asset Management LP raised its position in Jazz Pharmaceuticals by 7.7% in the 1st quarter. Readystate Asset Management LP now owns 22,869 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after purchasing an additional 1,635 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the sale, the director directly owned 408,826 shares in the company, valued at $57,235,640. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Up 6.1%

Shares of NASDAQ:JAZZ opened at $180.52 on Wednesday. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The firm’s 50-day simple moving average is $135.92 and its 200-day simple moving average is $121.19. The company has a market cap of $10.97 billion, a price-to-earnings ratio of -26.82, a PEG ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.11 billion. During the same period in the prior year, the company posted $6.54 earnings per share. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. As a group, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on JAZZ shares. Royal Bank Of Canada set a $194.00 price objective on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Monday. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Truist Financial raised their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Morgan Stanley boosted their price target on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Wells Fargo & Company upped their price objective on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $195.07.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.